Shares of Intellia Therapeutics (NASDAQ:NTLA) surged 8.06% in premarket trading on Thursday as the gene-editing company reported better-than-expected fourth-quarter results and provided updates on the robust progress across its pipeline candidates.
For the fourth quarter, Intellia reported a narrower-than-expected loss of $1.27 per share, beating analysts' estimate of a $1.36 loss. Collaboration revenue also exceeded expectations, coming in at $12.9 million, compared to the consensus estimate of $8.53 million.
More importantly, Intellia provided promising updates on its key pipeline programs, including NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis. The company dosed the first patient in the global Phase 3 HAELO study for NTLA-2002, with plans to complete enrollment in the second half of 2025 and submit a Biologics License Application in the second half of 2026 for a potential U.S. launch in 2027. Meanwhile, enrollment in the pivotal Phase 3 MAGNITUDE trial for nex-z in ATTR amyloidosis with cardiomyopathy is tracking ahead of projections, with over 550 total patients expected to be enrolled by year-end.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.